Michael G Wheaton1,2,3, Marina Gershkovich2,3, Thea Gallagher4, Edna B Foa4, H Blair Simpson2,3. 1. Barnard College, New York, NY, USA. 2. New York State Psychiatric Institute, New York, NY, USA. 3. Columbia Psychiatry, Columbia University, New York, NY, USA. 4. University of Pennsylvania, Philadelphia, PA, USA.
Abstract
BACKGROUND: Many individuals with obsessive-compulsive disorder (OCD) display behavioral avoidance related to their obsessional thoughts and compulsive behaviors. However, how these avoidance behaviors impact treatment outcomes with exposure and response prevention (EX/RP) remains unclear. We examined pretreatment avoidance behaviors as predictors of EX/RP outcomes. METHODS: Data came from a randomized controlled trial of augmentation strategies for inadequate response to serotonin reuptake inhibitors comparing EX/RP (N = 40), risperidone (N = 40), and placebo (N = 20). Baseline avoidance was rated with the avoidance item from the Yale-Brown Obsessive-Compulsive Scale (YBOCS). Primary analyses examined avoidance behaviors as predictors of EX/RP outcomes. To test specificity, we explored whether avoidance also related to outcomes among patients receivingrisperidone and placebo. RESULTS: More than half (69%) of the full sample had moderate or severe avoidance behaviors at baseline. In EX/RP, controlling for baseline severity, pretreatment avoidance predicted posttreatment YBOCS symptoms (β = 0.45, P < .01). Avoidant individuals were less likely to achieve remission with EX/RP (odds ratio = 0.04, 95% confidence interval [CI] range 0.01-0.28, P = .001). Baseline avoidance was also associated with degree of patient adherence to between-session EX/RP assignments, which mediated the relationship between baseline avoidance and EX/RP outcomes (P < .05). Baseline avoidance did not predict outcomes or wellness among patients receivingrisperidone or placebo. CONCLUSIONS: These results suggest that avoidance behaviors are an important clinical factor in EX/RP outcomes and indicate that assessing avoidance may provide an efficient method for predicting EX/RP outcomes. Avoidance may be particularly relevant in EX/RP as compared to medication treatment, though future replication of these initial results is required.
RCT Entities:
BACKGROUND: Many individuals with obsessive-compulsive disorder (OCD) display behavioral avoidance related to their obsessional thoughts and compulsive behaviors. However, how these avoidance behaviors impact treatment outcomes with exposure and response prevention (EX/RP) remains unclear. We examined pretreatment avoidance behaviors as predictors of EX/RP outcomes. METHODS: Data came from a randomized controlled trial of augmentation strategies for inadequate response to serotonin reuptake inhibitors comparing EX/RP (N = 40), risperidone (N = 40), and placebo (N = 20). Baseline avoidance was rated with the avoidance item from the Yale-Brown Obsessive-Compulsive Scale (YBOCS). Primary analyses examined avoidance behaviors as predictors of EX/RP outcomes. To test specificity, we explored whether avoidance also related to outcomes among patients receiving risperidone and placebo. RESULTS: More than half (69%) of the full sample had moderate or severe avoidance behaviors at baseline. In EX/RP, controlling for baseline severity, pretreatment avoidance predicted posttreatment YBOCS symptoms (β = 0.45, P < .01). Avoidant individuals were less likely to achieve remission with EX/RP (odds ratio = 0.04, 95% confidence interval [CI] range 0.01-0.28, P = .001). Baseline avoidance was also associated with degree of patient adherence to between-session EX/RP assignments, which mediated the relationship between baseline avoidance and EX/RP outcomes (P < .05). Baseline avoidance did not predict outcomes or wellness among patients receiving risperidone or placebo. CONCLUSIONS: These results suggest that avoidance behaviors are an important clinical factor in EX/RP outcomes and indicate that assessing avoidance may provide an efficient method for predicting EX/RP outcomes. Avoidance may be particularly relevant in EX/RP as compared to medication treatment, though future replication of these initial results is required.
Authors: Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas Journal: JAMA Psychiatry Date: 2013-11 Impact factor: 21.596
Authors: Bunmi O Olatunji; David Rosenfield; Candyce D Tart; Jean Cottraux; Mark B Powers; Jasper A J Smits Journal: J Consult Clin Psychol Date: 2013-02-18
Authors: Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Deborah Roth Ledley; Jonathan D Huppert; Shawn Cahill; Donna Vermes; Andrew B Schmidt; Elizabeth Hembree; Martin Franklin; Raphael Campeas; Chang-Gyu Hahn; Eva Petkova Journal: Am J Psychiatry Date: 2008-03-03 Impact factor: 18.112
Authors: W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney Journal: Arch Gen Psychiatry Date: 1989-11
Authors: Robert R Selles; Davið R M A Højgaard; Tord Ivarsson; Per Hove Thomsen; Nicole Michelle McBride; Eric A Storch; Daniel Geller; Sabine Wilhelm; Lara J Farrell; Allison M Waters; Sharna Mathieu; S Evelyn Stewart Journal: J Am Acad Child Adolesc Psychiatry Date: 2019-06-20 Impact factor: 8.829
Authors: Lily A Brown; Emily Wakschal; Stefanie Russman-Block; Christina L Boisseau; Maria C Mancebo; Jane L Eisen; Steven A Rasmussen Journal: J Affect Disord Date: 2018-11-13 Impact factor: 4.839
Authors: Gregory S Vogt; Michelle Avendaño-Ortega; Sophie C Schneider; Wayne K Goodman; Eric A Storch Journal: J Psychiatr Pract Date: 2022-07-01 Impact factor: 1.841